<DOC>
	<DOCNO>NCT00722137</DOCNO>
	<brief_summary>This randomize , open-label , multicentre , prospective study compare efficacy safety combination VcR-CAP R-CHOP participant newly diagnose mantle cell lymphoma grade II , III IV ineligible undergo bone marrow transplantation .</brief_summary>
	<brief_title>Study Combination Rituximab , Cyclophosphamide , Doxorubicin , VELCADE , Prednisone Rituximab , Cyclophosphamide , Doxorubicin , Vincristine , Prednisone Patients With Newly Diagnosed Mantle Cell Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<criteria>• Male female patient 18 year old ( patient must least legal age limit able give inform consent within jurisdiction study take place ) • Diagnosis MCL ( Stage II , III IV ) evidence lymph node histology either expression cyclin D1 ( association CD20 CD5 ) evidence ( 11 ; 14 ) translocation , cytogenetics , fluorescent situ hybridization ( FISH ) polymerase chain reaction ( PCR ) . Patients diagnosis Stage I MCL permit enter study . Paraffin embed biopsy tissue block ( preferably lymph node origin ) must send central laboratory confirmation MCL diagnosis prior randomization . In China , paraffin embed lymph node biopsy tissue block must send central confirmation sample adequacy , prior randomization At least 1 measurable site disease No prior therapy MCL Not eligible bone marrow transplantation assess treat physician ( e.g. , age presence comorbid condition may negative impact tolerability transplantation ) . Eastern Cooperative Oncology Group ECOG status ≤2 ( Attachment 1 ) Absolute neutrophil count ( ANC ) ≥1500 cells/µL , Platelets ≥100,000 cells/µL ≥75,000 cells/µL thrombocytopenia consider investigator secondary MCL ( e.g. , due bone marrow infiltration sequestration splenomegaly ) . Alanine transaminase ≤3 x upper limit normal ( ULN ) Aspartate transaminase ≤3 x ULN Total bilirubin ≤1.5 x ULN , Calculated creatinine clearance ≥20 mL/min . ( Attachment 2 ) Female patient must post menopausal least 1 year ( must natural menses least 12 month ) , surgically sterile , practice effective method birth control ( e.g. , prescription oral contraceptive , contraceptive injection , intrauterine device , doublebarrier method , contraceptive patch , male partner sterilization ) negative serum βHCG urine pregnancy test screening . They must also prepared continue birth control measure least 6 month terminate treatment . Male patient must agree use acceptable method contraception ( female partner list ) duration study . All patient ( legally acceptable representative ) must sign informed consent document indicate understand purpose procedure require study willing participate study . In order participate pharmacogenomics component study , patient ( legally acceptable representative ) must sign informed consent form pharmacogenomics research indicate willingness participate pharmacogenomics component study . Acquisition tumor sample collection require patient ( available ) ; sample collection optional Excl criterion EUCTR follow : Potential patient meet follow criterion exclude participate study : Prior treatment VELCADE Prior antineoplastic ( include unconjugated therapeutic antibody ) , experimental radiation therapy , radioimmunoconjugates toxin immunoconjugates treatment MCL . In event patient receive doxorubicin treatment condition , MCL , maximum dose exposure receive prior entry study exceed 150 mg/m2 . short course ( maximum 10 day , exceed 100 mg/day ) prednisone equivalent steroid allow treat symptom patient advanced disease enter screen phase wait randomize . Major surgery ( discretion treat physician consultation sponsor 's medical monitor ) within 2 week randomization Peripheral neuropathy neuropathic pain Grade 2 worse ( per investigator assessment ) Diagnosed treated malignancy MCL within 1 year randomization , previously diagnose malignancy MCL radiographic biochemical marker evidence malignancy . Patients completely resect basal cell carcinoma , squamous cell carcinoma skin , situ malignancy exclude . Active systemic infection require treatment patient know diagnosis HIV active hepatitis B ( carrier hepatitis B permit enter study ) History allergic reaction attributable compound contain boron , mannitol , hydroxybenzoates Known anaphylaxis immunoglobulin E ( IgE ) mediate hypersensitivity murine proteins component rituximab include polysorbate 80 sodium citrate dihydrate Female male patient childbearing potential use adequate contraception course study . Serious medical ( e.g. , pericardial disease , cardiac failure [ New York Heart Association ; NYHA Class III IV , Attachment 12 leave ventricular ejection fraction ; LVEF &lt; 50 % ] , active peptic ulceration , uncontrolled diabetes mellitus , acute diffuse infiltrative pulmonary disease ) , psychiatric illness likely interfere participation clinical study Concurrent treatment another investigational agent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>